#biopharma — Public Fediverse posts

GSK raises profit outlook on strong vaccine, HIV drug sales—Pfizer beats Q1 forecast despite 20% revenue drop, cuts four pipeline programs —Astellas adds to ‘off-the-shelf’ cell therapy capabilities with Poseida deal--http://bit.ly/w28kSd #earnings #gsk #pfizer #hiv #vaccines #celltherapy #astellas #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

GSK raises profit outlook on strong vaccine, HIV drug sales—Pfizer beats Q1 forecast despite 20% revenue drop, cuts four pipeline programs —Astellas adds to ‘off-the-shelf’ cell therapy capabilities with Poseida deal--http://bit.ly/w28kSd #earnings #gsk #pfizer #hiv #vaccines #celltherapy #astellas #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

GSK buying Aiolos for $1.4B to boost asthma pipeline —Bristol Myers Squibb CEO Boerner emphasizes organic pipeline over recent M&A deals— FDA declines to approve Astellas' gastric cancer drug --http://bit.ly/w28kSd #gsk #asthma #mergersandacquisitions #bristolmyerssquibb #fda #gastriccancer #astellas #jpmhc24 #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

After a record run, fewer biotechs are going public-- Merck, Astellas and Pfizer bring down the house with Keytruda-Padcev FDA nod in bladder cancer— 8 medtech trends to watch in 2024 --http://bit.ly/w28kSd #ipos #merck #astellas #pfizer #bladdercancer #medtech #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

AbbVie pays $10B to acquire ImmunoGen, doubling down on red-hot ADC cancer field-- Biopharma’s top 5 IPOs of 2023 so far --Astellas builds case for menopause drug fezolinetant http://bit.ly/w28kSd #abbvie #mergersandacquisitions #immunogen #ipos #menopause #astellas #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Astellas pays $175M for Propella, clearing early-phase rival to J&J's Zytiga for takeoff -- Vertex, CRISPR win world’s first approval for CRISPR-edited therapy from UK --BMS gets US approval for ROS1 lung cancer drug Augtyro-- See more on our front page news http://bit.ly/w28kSd #astellas #vertexpharma #crispr #geneediting #bristolmyerssquibb #lungcancer #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Seagen, Astellas and Merck knock it out of the park with Padcev-Keytruda combo in bladder cancer-- BrainStorm eyes FDA meeting to find path for rejected ALS drug after withdrawing application --Amazon will start delivering prescriptions by drone -- See more on our front page news http://bit.ly/w28kSd #seagen #astellas #merck #keytruda #esmo #bladdercancer #als #fda #amazon #drones #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Why a hidden message in Ozempic’s logo represents a big shift in drug branding -- Merck, Seagen, and Astellas get late-stage win in bladder cancer -- Merck and Eisai's Keytruda-Lenvima combo chalks up 2 more losses -- See more on our front page news http://bit.ly/w28kSd #ozempic #logo #novonordisk #branding #merck #seagen #astellas #bladdercancer #clinicaltrials #eisai #lungcancer #keytruda #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Massachusetts' biotech job boom -- Astellas withdraws lawsuit challenging Medicare drug price negotiation plans -- Pfizer ticks off Lyme vaccine milestone -- See more on our front page news http://bit.ly/w28kSd #massachusetts #astellas #medicare #drugpricing #inflationreductionact #lymedisease #vaccines #clinicaltrials #pfizer #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Biogen to eliminate 1,000 jobs in further cost cuts -- Cognizant, Gilead extend service agreement worth $800M -- Astellas notches another protein degrader pact with $21M upfront for PeptiDream -- See more on our front page news http://bit.ly/w28kSd #biogen #layoffs #gileadsciences #astellas #proteindegradation #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Pfizer, Seagen kick off antitrust review of $43B merger. Will FTC get on board? —FDA advisers narrowly vote in favor of Sarepta's DMD gene therapy —Astellas' menopause drug scores FDA approval, after regulatory setback -- See more on our front page news http://bit.ly/w28kSd #pfizer #seagen #antitrust #mergersandacquisitions #fda #hotflashes #genetherapy #menopause #astellas #dmd #sarepta #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Astellas to acquire eye drug developer Iveric Bio for $5.9B —With negative FDA panel vote, AstraZeneca's Lynparza looks set for narrow nod in prostate cancer—Otsuka, Lundbeck gain FDA nod for longer-acting version of schizophrenia drug Abilify -- See more on our front page news http://bit.ly/w28kSd #astellas #mergersandacquisitions #eyehealth #fda #prostatecancer #astrazeneca #abilify #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

FDA approves Keytruda/Padcev combo in advanced urothelial cancer — Record growth in U.S. life sciences real estate footprint — Diabesity drugs and their free ‘contract sales force’ -- See more on our front page news http://bit.ly/w28kSd #fda #merck #astellas #urothelialcancer #realestate #diabetes #obesity #novonordisk #elililly #keytruda #lifesciences #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

US again spurns march-in campaign to slash cost of Pfizer, Astellas' Xtandi — Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test— Boston Scientific, Medtronic expected to quickly capture new atrial fibrillation market -- See more on our front page news http://bit.ly/w28kSd #pfizer #astellas #prostatecancer #roche #elililly #diagnostics #medtech #alzheimers #atrialfibrillation #afib #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Alzheimer's Association campaigns for broader Leqembi coverage — FDA reverses course; will hold adcomm for Sarepta’s DMD gene therapy— Pfizer and Astellas report positive data from prostate cancer therapy trial -- See more on our front page news http://bit.ly/w28kSd #alzheimers #eisai #biogen #fda #dmd #duchenne #pfizer #astellas #clinicaltrials #prostatecancer #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Vaccines slip, Dupixent climbs for Sanofi as it readies multiple launches in 2023 — Astellas taps new CEO —Biogen and Sage get FDA priority review of depression med zuranolone -- See more on our front page news http://bit.ly/w28kSd #sanofi #earnings #druglaunches #astellas #ceos #biogen #sagetherapeutics #fda #depression #postpartumdepression #priorityreview #pharma #pharmanews #biotech #biotechnology #biopharma #cafepharma

AZ wins patent fight with Viatris, gains more exclusivity for blockbuster Symbicort — AbbVie leaves PhRMA, BIO: reports —Astellas’ Phase III gastric cancer therapy trial meets primary endpoint -- See more on our front page news http://bit.ly/w28kSd #astrazeneca #patents #Symbicort #BIO #PhRMA #abbvie #astellas #clinicaltrials #gastriccancer #pharma #pharmanews #biotech #biotechnology #biopharma #cafepharma